Aardvark Therapeutics (AARD) vs Polaryx Therapeutics (PLYX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aardvark Therapeutics is the larger company by market cap ($103.1 million vs $99.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | PLYX |
|---|---|---|
| Share price | $4.71 | $2.00 |
| Market cap | $103.08M | $99.69M |
| 1-day change | -5.04% | -4.31% |
| YTD return | -64.11% | — |
| 1-year return | -72.50% | — |
| EPS (TTM) | $-3.21 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $48.91 |
| 52-week low | $3.35 | $1.85 |
| Distance from 52-week high | -72.38% | -95.91% |
| Analyst consensus | buy | none |
| Avg. price target upside | +135.88% | +275.00% |
| Average volume | 208.11K | 76.41K |
| Shares outstanding | 21.88M | 49.85M |
| Employees | 28 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Healthcare · Biotechnology · 28 employees
About Polaryx Therapeutics
PLYX stock →Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate.
Healthcare · Biotechnology · 2 employees
AARD vs PLYX FAQ
Which is bigger, Aardvark Therapeutics or Polaryx Therapeutics?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $103.08M compared with $99.69M for Polaryx Therapeutics (PLYX).
Are Aardvark Therapeutics and Polaryx Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.